Navigating Patent Strategy Under the Inflation Reduction Act of 2022

The Inflation Reduction Act was signed into law by President Biden in August 2022 in an effort to curb inflation. While it made no direct changes to patent law, the Act will have an impact on pharmaceutical patent strategy and pricing.  In this conversation, the presenters will review the pertinent sections of the Act that directly impact the life sciences community and discuss the potential ramifications on patent strategy, including the possibility of litigation delays and the impact on recoverable damages.

Learning Objectives: 

1. Analyze the sections of the Inflation Reduction Act that directly affect the life sciences community, with a focus on pharmaceutical pricing and market dynamics
2. Explore how the Act may influence patent filing strategies, lifecycle management, and innovation in the pharmaceutical industry
3. Discuss how the Act might lead to changes in litigation timelines, strategies, and recoverable damages related to pharmaceutical patents
4. Consider the broader implications of the Act on regulatory compliance, competition, and the future of pharmaceutical innovation